SMART MONEY GROUP

[TheFinalCD]

XOMA .98 "PIPER JAFFRAY" RAISES PRICE TARGET TO $1.50

XOMA price target raised to $1.50 from $1 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for XOMA (XOMA) to $1.50 after the company partnered a preclinical TGF-beta antibody with Novartis (NVS) for $37M upfront and up to $480M in milestones. The payment brings XOMA's pro forma cash to $88M, enabling the company to advance its endocrine antibody pipeline, including lead candidate XOMA 358 for hyperinsulinism disorders, Tenthoff tells investors in a research note. The analyst keeps a Neutral rating on the name. The stock is up 20c to 95c in early trading. :theflyonthewall.com

http://www.marketwatch.com/story/xoma-enters-exclusive-license-agreement-with-novartis-2015-10-01-7914627?siteid=yhoof2